Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DC Bio is a South Korean biotechnology company specializing in the development of advanced molecular diagnostic solutions for early cancer detection. Utilizing its proprietary liquid biopsy platform, DC-Check, the company identifies specific DNA methylation biomarkers in blood or stool samples to screen for various malignancies, including colorectal, lung, and breast cancers. Founded in 2018 and headquartered in Seoul, DC Bio leverages high-sensitivity methylation-specific PCR (MSP) technology to provide non-invasive and accurate diagnostic tools. The company's mission is to facilitate early intervention and improve patient survival rates through accessible and reliable screening technologies. DC Bio is currently expanding its clinical validation studies and pursuing global commercialization opportunities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DC Bio.